•  
  •  
 

Abstract

Background: Colorectal cancer (CRC) remains a leading cause of global cancer mortality, with nearly 50% of patients progressing to metastatic disease (mCRC). High mortality in mCRC is driven by therapeutic resistance and limited durable treatment options. We investigated the efficacy of a novel inhibitor, Compound 1, targeting cathepsins L and S, to enhance the apoptotic response to standard-of-care oxaliplatin.Methods: The antiproliferative actions of compound 1 were evaluated across a panel of CRC cell lines, including HCT-116, RKO, SW480, and SW620. Furthermore, its combination with oxaliplatin was performed specifically in the metastatic SW620 cell line to evaluate synergy. Wound healing assays were conducted in SW620 cells to assess dose-dependent effects on migration over 96 hours. Molecular mechanisms were characterized using qPCR and Western blot to quantify markers for apoptosis (BCL2, BAX, p53, Caspases 3/9) and autophagy (LC3B, SQSTM1, ATG family).Results: Compound 1 inhibits the metastatic CRC cell line SW620 at sub-micromolar concentrations (IC₅₀ ~0.7 µM), while non-metastatic colorectal cancer and other solid tumor cell lines, require higher concentrations (~5 µM) for comparable growth inhibition. In SW620 cells, 1 significantly inhibited wound healing in a time- and dose-dependent manner. The combination of 3.45 µM 1 and 1.23 µM oxaliplatin yielded synergistic antiproliferative effects. Mechanistically, the combination significantly downregulated anti-apoptotic BCL2 mRNA and protein levels (p < 0.001) and increased the ratio of cleaved Caspase-3 and Caspase-9. While mTOR expression was not significantly altered, a reduction in key autophagy drivers (ATG3, ATG7, ATG10, SQSTM1) suggests an inhibitory effect on the autophagy pathway.Conclusion: Our findings identify compound 1 as a potent cathepsin inhibitor with significant activity against metastatic CRC cells. The synergy observed with oxaliplatin in SW620 cells driven by the sensitization of apoptotic pathways and inhibition of cell motility suggests compound 1 is a promising candidate for further in vivo investigation to overcome chemoresistance in metastatic colorectal cancer.

Included in

Life Sciences Commons

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.